In the past decade, recombinant vectors based on a non-pathogenic parvovirus, the adeno-
associated virus (AAV), have taken center stage as a gene delivery vehicle for the potential …

Enzymes are the large biomolecules that are required for the numerous chemical
interconversions that sustain life. They accelerate all the metabolic processes in the body …

Adeno-associated virus (AAV) is a small, nonenveloped virus that was adapted 30 years
ago for use as a gene transfer vehicle. It is capable of transducing a wide range of species …

Adeno-associated virus (AAV) vectors have emerged as a gene-delivery platform with
demonstrated safety and efficacy in a handful of clinical trials for monogenic disorders …

The unique life cycle of adeno-associated virus (AAV) and its ability to infect both
nondividing and dividing cells with persistent expression have made it an attractive vector …

Recombinant adeno-associated viral (AAV) vectors have rapidly advanced to the forefront of
gene therapy in the past decade. The exponential progress of AAV-based vectors has been …

Adeno-associated virus (AAV) is the leading vector in emerging treatments of inherited
diseases. Higher transduction efficiencies and cellular specificity are required for broader …

The adeno-associated virus (AAV) is a small, nonpathogenic parvovirus, which depends on
helper factors to replicate. Those helper factors can be provided by coinfecting helper …

Phospholipase A2 (PLA2) constitutes a growing superfamily of lipolytic enzymes, and to
date, at least 19 distinct enzymes have been found in mammals. This class of enzymes has …

The limited packaging capacity of adeno-associated virus (AAV) precludes the design of
vectors for the treatment of diseases associated with larger genes. Autonomous …